Overview

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants

Status:
Completed

Trial end date:
2018-09-21

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether roxadustat is safe and effective in the treatment of anemia in participants who have just begun dialysis treatment for ESRD.

Phase:

Phase 3

Details

Lead Sponsor:

FibroGen

Collaborators:

Astellas Pharma Europe B.V.
AstraZeneca

Treatments:

Epoetin Alfa